Several other equities research analysts have also commented on the stock. Zacks Investment Research raised shares of Kura Oncology from a hold rating to a buy rating and set a $10.00 price objective on the stock in a research note on Thursday, May 18th. Cann reissued a buy rating and set a $16.00 price objective on shares of Kura Oncology in a research note on Monday, May 15th. Finally, Oppenheimer Holdings, Inc. reissued an outperform rating and set a $16.00 price objective on shares of Kura Oncology in a research note on Friday, April 21st. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $14.60.
Shares of Kura Oncology (NASDAQ:KURA) opened at 6.40 on Tuesday. The firm’s market cap is $125.87 million. The company has a 50 day moving average of $9.07 and a 200-day moving average of $8.62. Kura Oncology has a 12-month low of $4.00 and a 12-month high of $12.10.
Kura Oncology (NASDAQ:KURA) last announced its earnings results on Monday, August 7th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. Analysts predict that Kura Oncology will post ($1.64) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Citigroup Inc. Reiterates $13.00 Price Target for Kura Oncology, Inc. (NASDAQ:KURA)” was first reported by Stock Observer and is owned by of Stock Observer. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.thestockobserver.com/2017/08/12/citigroup-inc-reiterates-13-00-price-target-for-kura-oncology-inc-nasdaqkura.html.
A number of large investors have recently bought and sold shares of KURA. Morgan Stanley raised its stake in Kura Oncology by 175.5% in the first quarter. Morgan Stanley now owns 430,428 shares of the company’s stock valued at $3,788,000 after buying an additional 274,166 shares during the last quarter. Northern Trust Corp raised its stake in Kura Oncology by 939.3% in the second quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock valued at $1,372,000 after buying an additional 133,293 shares during the last quarter. Alethea Capital Management LLC raised its stake in Kura Oncology by 128.1% in the second quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock valued at $1,798,000 after buying an additional 108,577 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in Kura Oncology during the first quarter valued at approximately $533,000. Finally, Vanguard Group Inc. raised its stake in Kura Oncology by 13.0% in the second quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock valued at $4,035,000 after buying an additional 50,033 shares during the last quarter. 50.17% of the stock is currently owned by institutional investors and hedge funds.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.